• Join
  • Login
  • Contact

Search abstracts

Design and optimisation of novel MEK inhibitors for the management of neoplastic disease using the tak-733 scaffold as a lead molecule

  • At: Seville (Spain) (2022)
  • Type: Poster
  • Poster code: APS-079
  • By: SHOEMAKE, Claire ()
  • Co-author(s): Mr Roderick Micallef, Pharmacy
    Dr Claire Shoemake, Senior Lecturer
  • Abstract:

    The mitogen-activated protein kinase signalling pathway is dysregulated in numerous human malignancies. Mutations exert their oncogenic activity through downstream proteins such as the MEK1/2 protein kinases. MEK inhibitors have been approved for clinical use in the treatment of BRAF-mutated melanoma, and are undergoing clinical trials for the..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses